Significant progress has been made in the past several decades in the perioperative management and the availability of improved diagnostic adjuncts such as imaging techniques and biochemical markers, but anastomotic complications, such as anastomotic leaks and strictures, which are often associated high morbidity and mortality, still continue to occur at a high rate[1, 2]. One of the main challenges is that the exact mechanisms impacting anastomotic healing are not yet fully understood[2]. Previous efforts have mainly focused on using engineering principles to promote device improvement and compound development (e.g., glues or seam bindings) to prevent the incidence of anastomotic complications. However, the iterative improvements in technology have had little impact on the incidence rates of anastomotic leaks and strictures[1]. In recent years, more and more studies have focused on the pathobiology of anastomotic complications at the cellular and molecular level[1–3].
Similar to other types of wound healing, inflammation, proliferation and remodeling are the three main phases of the intestinal healing process[4, 5]. The strength in the anastomosis is gradually enhanced as fibroblasts and smooth muscle cells in the healing tissue synthesize new collagen while the wound is remodeled. Any disturbance of that process may contribute to the development of anastomotic complications. More and more evidence shows that cell-to-cell signaling cross-talk plays essential roles in the regulation of this process mainly through cytokines and growth factors, including transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are released from the healing tissues[2]. Enhancement of these signaling pathways has been shown to improve anastomotic strength in animals, and the identification of new pathways to improve anastomotic healing has attracted the interest of researchers in recent years.
It is well known that the Hippo pathway and its downstream effectors, the transcriptional coactivator Yes associated protein (YAP) associated with its transcriptional coactivator with PDZ-binding motif (TAZ), play essential roles regulating the self-renewal and regeneration of different tissues, including the intestines, through the regulation of stem cell fate and cell proliferation and differentiation[6–9]. The activation of YAP/TAZ, the core components of the Hippo pathway, is controlled by two kinases, MST1 and MST2 (MST1/2), the mammalian Hippo orthologs. Therefore, chemical compounds that selectively target MST1/2 could induce tissue regeneration and enhance healing after injury. For example, 4-((5,10-dimethyl-6-oxo-6,10-dihydro-5H-pyrimido[5,4-b]thieno[3,2-e][1, 4] diazepin-2-yl)amino) benzenesulfonamide (XMU-MP-1), a selective MST1/2 inhibitor, has been shown to promote liver repair and regeneration after injury and to augment mouse intestinal repair as well[10]. Although the crucial function of the Hippo pathway in tissue regeneration has been studied intensively, little is known about the role of the Hippo pathway in intestinal anastomotic healing and regeneration to prevent anastomotic complications.
Shenhuang plaster (SHP), a traditional Chinese medicine formula, consists of seven herbs that are well documented since the earliest Chinese pharmaceutical monograph “ShenNong Ben Cao Jing”, including Sun-dried Panax ginseng, Salviae Miltiorrhzae Radix et Rhizoma, Rhubarb, Fructus Aurantii Immaturus, Cortex Magnoliae Officinalis, Flos Caryophyllata and Frutcus evodiae[11–13]. The HPLC profile of SHP revealed that it contained hesperidin, quercetin, ginsenoside-Rb1, aloeemodin, ginsenoside-Rg1, magnolol and chrysophanol. SHP has been widely used to treat abdominal obstructions and inflammatory bowel diseases with a prominent efficacy in clinics for more than 2 decades[14–16]. In clinical observation, our group found that the external application of SHP on Shenque (CV8), a method that has been used for more than 2,000 years[17], can shorten the first exhaust and defecation time, promote early rehabilitation of gastrointestinal dysfunction and intestinal peristalsis and relieve symptoms of gastrointestinal dysfunction in patients after abdominal surgery, for instance, SHP application in CV8 could significantly enhance bowel movement and improve constipation in breast cancer patients after surgery[14–16, 18]. In order to further understand the detail effect of SHP application on gastrointestinal function in patients after abdominal surgery, we and the other group have investigated the role of SHP in gastrointestinal function by using different animal models of postoperative ileus (POI), a gastrointestinal function complication that arises from surgery, for more than a decade. In the studies of POI rat models, we found transdermal application of SHP could improve gastrointestinal motility and significantly increase gut hormone ghrelin concentration and the expression of its receptor, but reduced obestatin concentration and the expression of GPR39 receptors in Blood[13, 19], and our study also showed that transdermal administration of SHP suppressed the intestinal inflammatory response and improved the impaired motility of the gastrointestine[12]; Further study of a rat model of POI showed that SHP application suppressed the expression of inflammatory mediators, including IL-10, TNF-α, IL-1β, IL-6, iNOS and ICAM-1[12, 20]. The studies from a mouse POI model showed SHP could enhance gastrointestinal motility by effectively regulating intestinal flora[21], And SHP could significantly decrease the expressions of interleukin (IL)- 1β and tumor necrosis factor (TNF)-α in the intestine with promotion of gastrointestinal motility is promoted, the suppression of inflammation of POI by SHP treatment likely through inhibition of the PI3K/AKT/NF-kB pathways[11]. In a tumor-bearing mouse model, we showed SHP could alleviate paclitaxel (PTX)-induced constipation and intestinal morphological damage through regulation of the expression of cytokines of TLR4 pathway and IL-1β[13]. In summary, the previous studies demonstrated that transdermal administration of SHP could improve gastrointestinal function and suppress inflammatory response in in vivo animal model of POI.
Based on above in vivo studies, we proposed that SHP might potentially benefit intestinal healing, which could prevent the occurrence of anastomotic complications. Therefore, the aims of the present study were to investigate whether SHP could enhance anastomotic healing, to explore the potential role of the Hippo pathway in intestinal anastomotic healing using an MST1/2 inhibitor XMU-MP-1, and to investigate the potential molecular mechanisms of SHP in the regulation of anastomotic healing.